Emmaus Life Sciences is seeking the approval of Endari (L-glutamine), an oral treatment for sickle cell disease…
Articles by Marisa Wexler, MS
GPH101, Graphite Bio’s investigational gene editing therapy, is able to correct the disease-causing mutation in blood stem cells of…
The National Institutes of Health (NIH) has awarded a $10.5-million grant to support several research projects seeking to improve care…
The Sickle Cell Consortium, a U.S.-based nonprofit, is hosting a virtual event in late August that will focus on…
Endari (L-glutamine), an approved oral treatment for sickle cell disease (SCD), has now been added to the Preferred…
Emmaus Life Sciences has submitted an application seeking the approval of its oral medication Endari (L-glutamine) to treat…
A new research collaboration between Jasper Therapeutics and Aruvant Sciences will evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody,…
Bluebird Bio is set to resume trials of LentiGlobin, its investigational gene therapy for sickle cell disease, after…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
A spoken word poetry contest is welcoming submissions from people with sickle cell disease (SCD) and their caregivers. The…